Stockscreener 앱 받기
0.8164
3.18%
-0.0268
시장 영업 전:
.83
0.0136
+1.67%
Reviva Pharmaceuticals Holdings Inc 주식(RVPH)의 최신 뉴스
Reviva Pharmaceuticals Holdings (RVPH) price target decreased by 50.79% to 38.15 - MSN
D. Boral Capital downgrades Reviva Pharmaceuticals stock rating to hold - Investing.com
Reviva Pharmaceuticals Holdings (RVPH) price target decreased by 42.03% to 68.00 - MSN
Reviva Pharmaceuticals shares tumble after $9M public offering priced - MSN
Reviva Pharmaceuticals Holdings (RVPH) price target increased by 14.00% to 77.52 - MSN
RVPH Should I Buy - Intellectia AI
Maxim Group downgrades Reviva Pharmaceuticals Holdings (RVPH) - MSN
Reviva CEO to discuss brilaroxazine milestones in April 27 chat - Stock Titan
Reviva to Participate in a Fireside Chat Hosted by A.G.P. - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and Merck & Company (MRK) - The Globe and Mail
Maxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress Plans - Insider Monkey
What Analysts Say About Reviva (RVPH) Stock (Steady Decline) 2026-04-20Expert Stock Picks - Xã Thanh Hà
RVPH: Shareholder Letter Introduces New IP - Yahoo Finance
5 Oversold Biotech Stocks to Invest In Now - Insider Monkey
symbol__ Stock Quote Price and Forecast - CNN
Deal Dispatch: Amazon Buys Globalstar, Instacart Grabs Instaleap, QVC Announces BankruptcyAmazon.com - Benzinga
Reviva Announces Letter to Shareholders - Sahm
Reviva Pharmaceuticals raises $10M, extends cash runway to Q1 2027 - Investing.com Australia
Reviva Pharmaceuticals Pursues Patent Extension for Brilaroxazine to 2046 and Prepares for Key FDA Milestone in Schizophrenia Program - Minichart
Reviva Pharmaceuticals outlines patent and development plans for brilaroxazine By Investing.com - Investing.com Australia
Reviva Updates Brilaroxazine Strategy and Funding Outlook - TipRanks
Reviva Pharmaceuticals raises $10M, extends cash runway to Q1 2027 By Investing.com - Investing.com South Africa
Reviva Pharmaceuticals outlines patent and development plans for brilaroxazine - Investing.com
Reviva Announces patent filing, FDA alignment plans and RECOVER-2 timing - TradingView
Reviva (NASDAQ: RVPH) maps brilaroxazine IP push and Phase 3 timeline - Stock Titan
Aug Weekly: Is Reviva Pharmaceuticals Holdings Inc forming a bullish divergencePortfolio Gains Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Growth Report: Can Reviva Pharmaceuticals Holdings Inc sustain earnings growthMarket Risk Report & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Reviva Pharmaceuticals Holdings, Inc. (RVPHW) - Minichart
RVPH|Reviva Pharmaceuticals Holdings Inc|Price:0.885|Chg%:0.03 - TradingKey
Does Cobenfy Have the Potential to Become a Top Drug for BMY? - TradingView
Is institutional money flowing into Reviva (RVPH) Stock | Price at $0.79, Down 0.63%MA Crossover - Xã Thanh Hà
Short Squeeze: How do insiders feel about Reviva Pharmaceuticals Holdings Inc2026 Retail & Expert Approved Momentum Ideas - baoquankhu1.vn
Investment Recap: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant being accumulated by smart money2026 PreEarnings & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Energy Moves: Is Reviva Pharmaceuticals Holdings Inc Equity Warrant impacted by rising rates2026 Performance Recap & Reliable Breakout Forecasts - baoquankhu1.vn
Volume Summary: Will Reviva Pharmaceuticals Holdings Inc Equity Warrant outperform during market rallies2026 Technicals & Expert-Curated Trade Recommendations - baoquankhu1.vn
Aug Analyst Calls: Is now the right time to enter Reviva Pharmaceuticals Holdings Inc2026 Macro Impact & Weekly Return Optimization Plans - baoquankhu1.vn
Form S-3Registration statement under Securities Act of 1933 - ADVFN
Reviva Pharmaceuticals Holdings, Inc. (RVPHW) Fundamental Analysis - Meyka
Roth MKM Maintains Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Maintains Target Price $1 - Moomoo
0.14%
0.48%
자본화:
|
볼륨(24시간):